These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31588504)

  • 1. The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
    Lee AK; Woodward M; Wang D; Ohkuma T; Warren B; Sharrett AR; Williams B; Marre M; Hamet P; Harrap S; Mcevoy JW; Chalmers J; Selvin E
    J Clin Endocrinol Metab; 2020 Jan; 105(1):152-62. PubMed ID: 31588504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
    Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
    N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
    Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
    Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights from ADVANCE.
    Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
    J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
    Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
    J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
    Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
    Chalmers J; Arima H; Woodward M; Mancia G; Poulter N; Hirakawa Y; Zoungas S; Patel A; Williams B; Harrap S
    Hypertension; 2014 Feb; 63(2):259-64. PubMed ID: 24324048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
    Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
    ADVANCE Management Committee
    Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
    Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
    Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
    Rahman F; McEvoy JW; Ohkuma T; Marre M; Hamet P; Harrap S; Mancia G; Rodgers A; Selvin E; Williams B; Muntner P; Chalmers J; Woodward M
    Hypertension; 2019 Jun; 73(6):1291-1299. PubMed ID: 31030606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
    Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
    Poulter NR
    J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADVANCE: breaking new ground in type 2 diabetes.
    Chalmers J; Perkovic V; Joshi R; Patel A
    J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ADVANCE study: objectives, design and current status].
    Chalmers J
    Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
    Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
    Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; MacMahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S;
    Diabetes Care; 2016 May; 39(5):694-700. PubMed ID: 27006512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.
    ; Gregg EW; Jakicic JM; Blackburn G; Bloomquist P; Bray GA; Clark JM; Coday M; Curtis JM; Egan C; Evans M; Foreyt J; Foster G; Hazuda HP; Hill JO; Horton ES; Hubbard VS; Jeffery RW; Johnson KC; Kitabchi AE; Knowler WC; Kriska A; Lang W; Lewis CE; Montez MG; Nathan DM; Neiberg RH; Patricio J; Peters A; Pi-Sunyer X; Pownall H; Redmon B; Regensteiner J; Rejeski J; Ribisl PM; Safford M; Stewart K; Trence D; Wadden TA; Wing RR; Yanovski SZ
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):913-921. PubMed ID: 27595918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.